Binge Eating Disorder Clinical Trial
Official title:
A 12-week, Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder
A study to evaluate a drug (dasotraline) on the safety, effectiveness and how well the body tolerates it, in adults with moderate to severe binge eating disorder
This is a randomized, double-blind, parallel-group, multicenter, outpatient study evaluating
the efficacy and safety of 2 doses of dasotraline (4 and 6 mg/day) versus placebo over a
12-week treatment period in adults with BED. This study is projected to randomize
approximately 480 subjects to 3 treatment groups in a 1:1:1 ratio (4 mg/day dasotraline, 6
mg/day dasotraline, and placebo).
Subjects randomized to placebo will receive placebo for the duration of the treatment period.
Subjects randomized to 4 mg/day dasotraline will receive 4 mg/day for the duration of the
treatment period.
Subjects randomized to 6 mg/day dasotraline will be dosed with 4 mg/day dasotraline for the
first 2 weeks of the treatment period and will be increased to 6 mg/day at Week 2.
If, in the judgment of the Investigator, the subject does not tolerate the assigned dose, he
or she will be discontinued from the study.
The study will consist of 3 periods: Screening (up to 3 weeks), 12-weeks of treatment, and a
3-week study drug withdrawal period. Subjects who complete the 12-week double-blind treatment
period in this study may be eligible to enroll and continue treatment for an additional 12
months in an open-label extension study (Study SEP360-322). Subjects who do not enter the
extension study will complete the study drug withdrawal period in this study.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT02978742 -
Evaluating and Implementing a Smartphone Application Treatment Program for Bulimia Nervosa and Binge Eating Disorder
|
N/A | |
| Recruiting |
NCT02659488 -
Lisdexamfetamine in Binge Eating Disorder (BED): fMRI Effects
|
Phase 2 | |
| Completed |
NCT02659475 -
Phentermine/Topiramate Extended Release in Binge Eating Disorder (BED)
|
Phase 2 | |
| Completed |
NCT00601653 -
Effectiveness of Cognitive Behavioral Therapy Plus Nutritional Counseling in Promoting Weight Loss in People With Binge Eating Disorder
|
N/A | |
| Completed |
NCT02834299 -
Dialectical Behavior Therapy Guided Self-Help for Binge Eating Disorder
|
N/A | |
| Completed |
NCT02553824 -
FDA Approved Medication to Reduce Binge Eating and/or Purging
|
Phase 1 | |
| Completed |
NCT02564588 -
Dasotraline Binge Eating Disorder Study
|
Phase 2/Phase 3 | |
| Completed |
NCT00307190 -
Hormone Release and Stomach Disturbances in People With Binge Eating Disorder
|
N/A | |
| Completed |
NCT01718483 -
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
|
Phase 3 | |
| Completed |
NCT01718509 -
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
|
Phase 3 | |
| Completed |
NCT02503098 -
Optimizing a Smartphone Application for Individuals With Eating Disorders
|
N/A | |
| Active, not recruiting |
NCT01837953 -
Stepped Care for Binge Eating Disorder: Predicting Response to Minimal Intervention in a Randomized Controlled Trial
|
N/A | |
| Completed |
NCT01010789 -
Armodafinil in Binge Eating Disorder (BED)
|
Phase 3 | |
| Completed |
NCT01098435 -
ALK33-101: A Study of RDC-0313 (ALKS 33) in Adults With Binge Eating Disorder
|
Phase 2 | |
| Completed |
NCT01552759 -
Appetite Hormones in Binge Eating Disorder
|
N/A | |
| Completed |
NCT00330655 -
An Open-Label Trial of Memantine in the Treatment of Binge Eating Disorder
|
Phase 4 | |
| Completed |
NCT01291173 -
Forced-dose Titration of SPD489 in Adults With Binge Eating Disorder
|
Phase 2 | |
| Completed |
NCT02079935 -
Treatment of Eating Disorders by Physical Activity and Nutrition Counseling
|
N/A | |
| Completed |
NCT00277641 -
Lamotrigine in the Treatment of Binge Eating Disorder Associated With Obesity
|
Phase 3 | |
| Completed |
NCT00032760 -
Meditation-Based Treatment for Binge Eating Disorder
|
Phase 2/Phase 3 |